APOE and Alzheimer disease: ApoE4 carriers tended to show higher values of both p3-Alcα and Aβ40 in MCI (CDR 0.5) and AD (CDR 1) patients but not in more advance AD (CDR 2–3) or in FTLD patients (Additional file 3, Figure S2).